Jan 24,2019

Stanford, VA Palo Alto Health Care System launch trial of digital depression therapy program

The acceptability, safety, feasibility and preliminary efficacy of Meru Health’s digital therapeutic for depression will be evaluated in a new two-year investigation conducted by Stanford Medicine and VA Palo Alto Health Care System researchers. According to a clinicaltrials.gov listing, the research program will enroll older adults aged at least 40 years with depressive symptoms in two studies.

PRODUCT

#mobile app

#cbt

View Analyst & Ambassador Comments
Go to original news
Aug 01,2018

Digital therapeutics are just what the doctor ordered for patients — and for global healthcare systems

It would be hard to argue that digital products have a net-positive impact on our health. The habit-forming power of digital products can be used for therapeutic benefit too, often by changing the behavior that causes disease or ill health. This new range of products is being commonly referred to as digital therapeutics. These apps and services offer evidence-based and personalized behavioral therapy, and cater to a broad cross-section of illnesses and conditions — from diabetes to loneliness, and everything in-between.

#cbt

#mobile app

View Analyst & Ambassador Comments
Go to original news
Feb 22,2018

2Morrow adds chronic pain management to its mobile behavior therapy offerings

As opioid abuse continues to make impact in the US, more and more tech-driven answers to the drug crisis are springing up that aim to reduce patients’ reliance on prescription opioids. Just yesterday, behavioral health therapy app maker 2Morrow threw its hat into the ring with the announcement that its services now include a digital chronic pain management program. Much like the company’s other offerings — which target smoking, weight, and stress — the pain management program is based on acceptance and commitment therapy (ACT), a clinically tested form of cognitive behavioral therapy that’s strongly endorsed by the Society of Clinical Psychology.

PRODUCT

#cbt

#mobile app

View Analyst & Ambassador Comments
Go to original news
Apr 11,2018

CureApp and HIKARI LAB Begins “ascureSPARX Mental Health Program”

CureApp which deals with the research and development of “Treatment Applications” as medical devices in treatment programs, together with HIKARI LAB Co., Ltd. which offers online counselling and smart phone applications for psychological care, have joined together to begin offering the “ascureSPARX Mental Health Program”. The “ascureSPARX Mental Health Program” is a psychological care and counseling program that combines a “doctor developed application” and “online counseling”.

COLLABORATION PARTNERSHIP

#institution

#cbt

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jun 27,2018

Quest, Omada Health Collaboration Shows One-Third in Workforce Study Reduced Risk for Diabetes

A study presented Monday at the American Diabetes Association (ADA) Scientific Sessions found that one-third of those who initially screened positive for prediabetes or diabetes were able to bring their blood sugar down to normal levels after taking part in a workforce-based intervention. The study by Quest Diagnostics, which involved a collaboration with the digital health provider Omada Health, shows promise for employer-based wellness programs that involve a 2-step process: screening for those at risk, and then offering an evidence-based program of lifestyle change and support for those whose health risks are revealed during screening.

CLINICAL STUDY

#cbt

#coaching

View Analyst & Ambassador Comments
Go to original news
Sep 25,2018

Big Health’s CBT app improves conditions of users with insomnia symptoms

A new dual-arm randomized trial published this morning in JAMA Psychiatry found that use of Big Health’s Sleepio app as a digital cognitive behavioral therapy (dCBT) led to significant improvements in self-reported functional health, psychological wellbeing, and sleep-related quality of life among those with symptoms to insomnia. Among a study group of 1,711 users, use of the Sleepio app appeared to drive improvements in self-reported functional health, psychological wellbeing, and sleep-related quality of life.

CLINICAL STUDY

#mobile app

#cbt

View Analyst & Ambassador Comments
Go to original news
Oct 12,2018

Some Apps May Help Curb Insomnia, Others Just Put You To Sleep

Sleepio and a few other apps like SHUT-i and a free one developed by the Veterans Administration use the most sustainable and evidence-based solution for insomnia. It's a kind of therapy called Cognitive Behavioral Therapy for Insomnia — CBT-I.

#mobile app

#cbt

View Analyst & Ambassador Comments
Go to original news
Oct 24,2018

Promising study results for digital behavioral therapies

Data from two clinical trials presented at the annual conference of the American College of Lifestyle Medicine give credence to digitally-delivered behavioral interventions developed by Better Therapeutics. The first observed an average A1c reduction of .8 percent among Type 2 diabetes patients receiving 12 weeks of the digital treatment. The other, conducted among hypertension patients, saw an average systolic blood pressure drop of 11.4 mmHg.

PRODUCT

#cbt

#pdt

View Analyst & Ambassador Comments
Go to original news
Nov 20,2018

Pear Therapeutics, Novartis announce commercial launch of reSET

reSET — a substance use disorder treatment that was the first software-only therapeutic cleared by the FDA — is now commercially available for clinicians to prescribe to their patients, according to a release from Pear Therapeutics and Sandoz, a division of Novartis with which Pear partnered back in April. As the first prescription digital therapeutic approved by the FDA, the treatment will be distributed and supported by a specialist-staffed service center.

PRODUCT

#mobile app

#pdt

#cbt

View Analyst & Ambassador Comments
Go to original news
Dec 10,2018

Pear's digital therapeutic reSET-O FDA cleared to treat opioid use disorder

The FDA has officially cleared reSET-O — a digital therapeutic to treat opioid use disorder (OUD) jointly developed by Pear Therapeutics and Sandoz, a division of Novartis — a little over a year after it was granted an Expedited Access Pathway designation from the agency. The prescription digital therapeutic will give users interactive therapy lessons to be use by patients under a clinician's supervision.

REGULATORY FDA

#mobile app

#pdt

#cbt

View Analyst & Ambassador Comments
Go to original news
Subscribe to CBT